Frontiers in Pharmacology,
Год журнала:
2022,
Номер
13
Опубликована: Май 31, 2022
Targeted
delivery
by
either
systemic
or
local
targeting
of
therapeutics
to
the
bone
is
an
attractive
treatment
for
various
metabolism
diseases
such
as
osteoporosis,
osteoarthritis,
osteosarcoma,
osteomyelitis,
etc.
To
overcome
limitations
direct
drug
delivery,
combination
bone-targeted
agents
with
nanotechnology
has
opportunity
provide
a
more
effective
therapeutic
approach,
where
engineered
nanoparticles
cause
accumulate
in
bone,
thereby
improving
efficacy
and
minimizing
side
effects.
Here,
we
summarize
current
advances
bone-targeting
approaches
nanosystem
applications
diseases,
which
may
new
insights
into
nanocarrier-delivered
drugs
targeted
diseases.
We
envision
that
novel
carriers
developed
based
on
will
be
potential
vehicle
currently
incurable
are
expected
translated
clinical
applications.
Theranostics,
Год журнала:
2022,
Номер
12(15), С. 6576 - 6594
Опубликована: Янв. 1, 2022
Bone
and
soft
tissue
tumors
are
complex
mesenchymal
neoplasms
that
seriously
endanger
human
health.
Over
the
past
decade,
relationship
between
microorganisms
health
diseases
is
getting
more
attention.
The
extracellular
vesicles
derived
from
bacteria
have
been
shown
to
regulate
bacterial-host
cell
communication
by
transferring
their
contents,
including
nucleic
acids,
proteins,
metabolites,
lipopolysaccharides,
peptidoglycans.
Bacteria
(BEVs)
promising
lipid-bilayer
nanocarriers
for
treatment
of
many
due
low
toxicity,
drug
loading
capacity,
ease
modification
industrialization.
Specially,
BEVs-based
cancer
therapy
has
attracted
much
attention
because
ability
effectively
stimulate
immune
responses.
In
this
review,
we
provide
an
overview
biogenesis,
composition,
isolation,
classification,
internalization
BEVs.
We
then
comprehensively
summarize
sources
BEVs
in
BEVs-related
strategies.
further
highlight
great
potential
bone
tumors.
Finally,
conclude
major
advantages
challenges
therapy.
believe
comprehensive
understanding
field
will
generate
innovative
solutions
achieve
clinical
applications.
Extracellular Vesicles and Circulating Nucleic Acids,
Год журнала:
2022,
Номер
3(1), С. 63 - 86
Опубликована: Янв. 1, 2022
Extracellular
vesicles
(EVs),
which
are
nanocarriers
with
phospholipid
bilayer
structures
released
by
most
cells,
play
a
key
role
in
regulating
physiological
and
pathological
processes.
EVs
have
been
investigated
due
to
their
loading
capacity,
low
toxicity,
immunogenicity,
biofunctions.
Although
shown
good
potential
as
therapeutic
vehicles,
natural
poor
targeting
ability,
substantially
reduces
the
effect.
Through
addition
of
unit
into
membrane
surface
or
inside
engineering
technology,
agent
can
accumulate
specific
cells
tissues.
Here,
we
focus
on
mammalian
(MEVs)
bacterial
(BEVs),
two
common
types
biomedical
field.
In
this
review,
describe
engineered
MEVs
BEVs
promising
for
targeted
therapy
summarize
biogenesis,
isolation,
characterization
BEVs.
We
then
techniques
enhancement
ability
EVs.
Moreover,
applications
therapy,
including
treatment
cancer
brain
bone
disease.
believe
that
review
will
help
improve
understanding
BEVs,
thereby
promoting
application
clinical
translation.
Frontiers in Pharmacology,
Год журнала:
2022,
Номер
13
Опубликована: Май 31, 2022
Targeted
delivery
by
either
systemic
or
local
targeting
of
therapeutics
to
the
bone
is
an
attractive
treatment
for
various
metabolism
diseases
such
as
osteoporosis,
osteoarthritis,
osteosarcoma,
osteomyelitis,
etc.
To
overcome
limitations
direct
drug
delivery,
combination
bone-targeted
agents
with
nanotechnology
has
opportunity
provide
a
more
effective
therapeutic
approach,
where
engineered
nanoparticles
cause
accumulate
in
bone,
thereby
improving
efficacy
and
minimizing
side
effects.
Here,
we
summarize
current
advances
bone-targeting
approaches
nanosystem
applications
diseases,
which
may
new
insights
into
nanocarrier-delivered
drugs
targeted
diseases.
We
envision
that
novel
carriers
developed
based
on
will
be
potential
vehicle
currently
incurable
are
expected
translated
clinical
applications.
